

Depression in adults: treatment and management

Appendix U2.13: Text from CG90 Appendix 19c that has been deleted

NICE Guideline

Appendices

May 2018

Disclaimer

Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer.

Copyright

National Institute for Health and Care Excellence [2018]. All rights reserved. Subject to Notice of rights.

Appendix 19c: Clinical evidence forest plots for pharmacology and other physical treatments

Contents


Amitriptyline	5
Antidepressants versus TCAs sub-analyses	45
Atypical depression sub-analyses.....	71
Augmentation with a benzodiazepine.....	83
Augmentation with buspirone.....	86
Augmentation with pindolol.....	87
Augmentation with triiodothyronine (T3)	98
Duloxetine.....	99
Dul.01 to 02. Duloxetine versus placebo - acute phase	99
Dul.03 to 04. Duloxetine comparing different doses - acute phase.....	119
Dul.05 to 06. Duloxetine versus other antidepressants - acute phase.....	127
Dul.07. Duloxetine versus placebo - continuation phase for partial responders	136
Dul.08. Duloxetine comparing different doses - continuation phase for partial responders	138
Dul.09. Duloxetine versus other antidepressants - continuation phase for partial responders.....	140
Dul.10. Duloxetine versus placebo - continuation phase for those achieving remission.....	142
Dul.11. Duloxetine versus other antidepressants - continuation phase for all.....	142
Escitalopram	145
Esc.01. Escitalopram versus placebo	145
Esc.02. Escitalopram versus all other antidepressants.....	152
Esc.04. Escitalopram versus non-SSRIs.....	169
Esc.05. Escitalopram versus all other antidepressants - citalopram separated	176
Esc.06. Escitalopram: overall efficacy - ordered by baseline severity	183
Esc.07. Escitalopram: overall acceptability and tolerability - ordered by baseline severity	187
Esc.08. Escitalopram: overall efficacy versus active treatment - by comparator drug	190
Esc.09. Escitalopram: overall acceptability and tolerability versus active treatment - by comparator drug	200
Esc.10. Escitalopram: overall efficacy - by dose	206
Esc.11. Escitalopram: overall acceptability and tolerability - by dose	210
Low dose TCAs	213

Mirtazapine.....	217
Moclobemide	263
Next-step treatments	303
Next step 01. Dose escalation	303
Next-step 02. Switching: continuing antidepressants versus switching	310
Next-step 03. Switching: switching to single or combination drugs	316
Next-step 04. Switching to a single drug	323
Next-step 05. Switching: single antidepressants versus augmentation strategy	324
Next-step 06. Switching: single antidepressants (open-label data).....	326
Next-step 07. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing)	331
Next-step 08. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing)	337
Next-step 09. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing).....	343
Next-step 10. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug - open-label data	348
Next-step 11. Comparisons involving CBT - open-label data.....	353
Next-step 12. Electroconvulsive therapy (ECT).....	357
Older adults sub-analyses.....	366
Phenelzine	412
Depression with psychotic features.....	425
Reboxetine.....	435
Relapse prevention	444
SSRIs versus antidepressants	524
SSRIs versus placebo	568
TCAs versus placebo	584
TCA.01. TCAs versus placebo - efficacy data.....	584
TCA.02. TCAs versus placebo - acceptability and tolerability data.....	590
Venlafaxine	593


Please note that due to the size of some of the forest plots you may need to use the zoom feature to view the data.

Amitriptyline


Review: Pharmacology: Amitriptyline
 Comparison: 01 Overall efficacy
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 01 Overall efficacy
 Outcome: 02 Mean scores at endpoint




Review: Pharmacology: Amitriptyline
 Comparison: 01 Overall efficacy
 Outcome: 03 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 01 Overall efficacy
 Outcome: 04 Mean scores at endpoint in inpatients




Review: Pharmacology: Amitriptyline
 Comparison: 01 Overall efficacy
 Outcome: 05 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 01 Overall efficacy
 Outcome: 06 Mean scores at endpoint in outpatients




Review: Pharmacology: Amitriptyline
 Comparison: 01 Overall efficacy
 Outcome: 07 Number of primary care patients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 01 Overall efficacy
 Outcome: 08 Mean scores at endpoint in primary care patients







Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 04 Inpatients leaving the study early




Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 05 Leaving the study early due to side effects in inpatients




Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 06 Inpatients reporting side effects




Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 07 Outpatients leaving the study early




Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 08 Leaving the study early due to side effects in outpatients




Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 09 Outpatients reporting side effects




Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 10 Primary care patients leaving the study early




Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 11 Leaving the study early due to side effects in primary care patients




Review: Pharmacology: Amitriptyline
 Comparison: 02 Overall tolerability
 Outcome: 12 Patients in primary care reporting side effects




Review: Pharmacology: Amitriptyline
 Comparison: 03 Efficacy against TCAs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 03 Efficacy against TCAs
 Outcome: 02 Mean scores at endpoint




Review: Pharmacology: Amitriptyline
 Comparison: 03 Efficacy against TCAs
 Outcome: 03 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 03 Efficacy against TCAs
 Outcome: 04 Mean scores at endpoint in inpatients




Review: Pharmacology: Amitriptyline
 Comparison: 03 Efficacy against TCAs
 Outcome: 05 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 03 Efficacy against TCAs
 Outcome: 06 Mean scores at endpoint in outpatients




Review: Pharmacology: Amitriptyline
 Comparison: 03 Efficacy against TCAs
 Outcome: 07 Mean scores at endpoint in primary care




Review: Pharmacology: Amitriptyline
 Comparison: 04 Tolerability against TCAs
 Outcome: 01 Leaving the study early




Review: Pharmacology: Amitriptyline
 Comparison: 04 Tolerability against TCAs
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Amitriptyline
 Comparison: 04 Tolerability against TCAs
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Amitriptyline
 Comparison: 04 Tolerability against TCAs
 Outcome: 04 Inpatients leaving the study early




Review: Pharmacology: Amitriptyline
 Comparison: 04 Tolerability against TCAs
 Outcome: 05 Leaving the study early due to side effects in inpatients




Review: Pharmacology: Amitriptyline
 Comparison: 04 Tolerability against TCAs
 Outcome: 06 Outpatients leaving the study early




Review: Pharmacology: Amitriptyline
 Comparison: 04 Tolerability against TCAs
 Outcome: 07 Leaving the study early due to side effects in outpatients




Review: Pharmacology: Amitriptyline
 Comparison: 04 Tolerability against TCAs
 Outcome: 08 Outpatients reporting side effects




Review: Pharmacology: Amitriptyline
 Comparison: 04 Tolerability against TCAs
 Outcome: 09 Leaving the study early in primary care




Review: Pharmacology: Amitriptyline
 Comparison: 04 Tolerability against TCAs
 Outcome: 10 Leaving the study early due to side effects in primary care




Review: Pharmacology: Amitriptyline
 Comparison: 05 Efficacy against SSRIs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 05 Efficacy against SSRIs
 Outcome: 02 Mean scores at endpoint




Review: Pharmacology: Amitriptyline
 Comparison: 05 Efficacy against SSRIs
 Outcome: 03 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 05 Efficacy against SSRIs
 Outcome: 04 Mean scores at endpoint in inpatients




Review: Pharmacology: Amitriptyline
 Comparison: 05 Efficacy against SSRIs
 Outcome: 05 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 05 Efficacy against SSRIs
 Outcome: 06 Mean scores at endpoint in outpatients




Review: Pharmacology: Amitriptyline
 Comparison: 05 Efficacy against SSRIs
 Outcome: 07 Mean scores at endpoint in primary care patients




Review: Pharmacology: Amitriptyline
 Comparison: 05 Efficacy against SSRIs
 Outcome: 08 Number of primary care patients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 01 Leaving the study early




Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 04 Inpatients leaving the study early




Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 05 Leaving the study early due to side effects in inpatients




Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 06 Inpatients reporting side effects




Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 07 Outpatients leaving the study early




Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 08 Leaving the study early due to side effects in outpatients




Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 09 Primary care patients leaving the study early



Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 10 Leaving the study early due to side effects in primary care patients




Review: Pharmacology: Amitriptyline
 Comparison: 06 Tolerability against SSRIs
 Outcome: 11 Primary care patients reporting side effects




Antidepressants versus TCAs sub-analyses


Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 02 Sensitivity analysis: Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 03 Number of people not achieving remission




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 04 Sensitivity analysis: Number of people not achieving remission




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 07 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 08 Sensitivity analysis: Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 09 Mean scores at endpoint in inpatients




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 10 Sensitivity analysis: Mean scores at endpoint in inpatients




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 11 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 12 Sensitivity analysis: Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 13 Number of outpatients not achieving remission




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 14 Sensitivity analysis: Number of outpatients not achieving remission




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 15 Mean scores at endpoint in outpatients




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 16 Sensitivity analysis: Mean scores at endpoint in outpatients




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)
 Outcome: 17 Mean scores at endpoint in primary care




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)
 Outcome: 04 Inpatients leaving the study early




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)
 Outcome: 05 Outpatients leaving the study early




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)
 Outcome: 06 Primary care patients leaving the study early




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)
 Outcome: 07 Inpatients leaving the study early due to side effects




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)
 Outcome: 08 Outpatients leaving the study early due to side effects




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)
 Outcome: 09 Primary care patients leaving the study early due to side effects




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)
 Outcome: 10 Inpatients reporting side effects



Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)
 Outcome: 11 Outpatients reporting side effects




Review: Pharmacology: Antidepressants versus TCAs
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)
 Outcome: 12 Primary care patients reporting side effects




Atypical depression sub-analyses


Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 01 Phenelzine v other antidepressants
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 01 Phenelzine v other antidepressants
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 01 Phenelzine v other antidepressants
 Outcome: 03 Mean end point scores




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 01 Phenzelzine v other antidepressants
 Outcome: 04 Leaving the study early




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 01 Phenzelzine v other antidepressants
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 02 Phenelzine v TCAs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 02 Phenelzine v TCAs
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 02 Phenzelzine v TCAs
 Outcome: 03 Mean end point scores




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 03 Phenzelzine v fluoxetine
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 03 Phenelzine v fluoxetine
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 03 Phenelzine v fluoxetine
 Outcome: 03 Mean end point scores




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 03 Phenelzine v fluoxetine
 Outcome: 04 Leaving the study early




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 03 Phenelzine v fluoxetine
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 04 Fluoxetine v other antidepressants
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 04 Fluoxetine v other antidepressants
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 04 Fluoxetine v other antidepressants
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 04 Fluoxetine v other antidepressants
 Outcome: 04 Leaving the study early




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 04 Fluoxetine v other antidepressants
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 05 Fluoxetine v TCAs
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 07 TCAs v other antidepressants
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score



Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 07 TCAs v other antidepressants
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Atypical depression sub-analysis
 Comparison: 07 TCAs v other antidepressants
 Outcome: 03 Mean endpoint scores




Augmentation with a benzodiazepine


Review: Pharmacology: Augmentation with a benzodiazepine
 Comparison: 01 Antidepressant + benzodiazepine v antidepressant + placebo: Efficacy
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Augmentation with a benzodiazepine
 Comparison: 01 Antidepressant + benzodiazepine v antidepressant + placebo: Efficacy
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Augmentation with a benzodiazepine
 Comparison: 01 Antidepressant + benzodiazepine v antidepressant + placebo: Efficacy
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Augmentation with a benzodiazepine
 Comparison: 02 Antidepressant + benzodiazepine v antidepressant + placebo: Tolerability
 Outcome: 01 Leaving the study early



Review: Pharmacology: Augmentation with a benzodiazepine
 Comparison: 02 Antidepressant + benzodiazepine v antidepressant + placebo: Tolerability
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Augmentation with a benzodiazepine
 Comparison: 02 Antidepressant + benzodiazepine v antidepressant + placebo: Tolerability
 Outcome: 03 Patients reporting side effects




Augmentation with buspirone

Review: Pharmacology: Refractory depression
 Comparison: 01 Patients whose depression has not responded to one adequate trial of an antidepressant
 Outcome: 32 Augmentation with buspirone: Leaving the study early




Review: Pharmacology: Refractory depression
 Comparison: 01 Patients whose depression has not responded to one adequate trial of an antidepressant
 Outcome: 33 Augmentation with buspirone: Leaving the study early due to side effects




Augmentation with pindolol


Review: Pharmacology: Augmentation with pindolol
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)
 Outcome: 01 Non-responders at early assessment point (day 10)




Review: Pharmacology: Augmentation with pindolol
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)
 Outcome: 02 Non-responders at late assessment point (days 35/42)




Review: Pharmacology: Augmentation with pindolol
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)
 Outcome: 03 Non-remitters at early assessment point (days 10/14)




Review: Pharmacology: Augmentation with pindolol
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)
 Outcome: 04 Non-remitters at late assessment point (days 21/28/42)




Review: Pharmacology: Augmentation with pindolol
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)
 Outcome: 05 Mean scores at early assessment point (day 10)




Review: Pharmacology: Augmentation with pindolol
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)
 Outcome: 06 Mean scores at late assessment point (days 21/35/42)




Review: Pharmacology: Augmentation with pindolol
 Comparison: 02 Tolerability: (SSRI + Pindolol) v (SSRI + placebo)
 Outcome: 01 Leaving the study early




Review: Pharmacology: Augmentation with pindolol
 Comparison: 02 Tolerability: (SSRI + Pindolol) v (SSRI + placebo)
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Augmentation with pindolol
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes
 Outcome: 01 Non-responders at early assessment point




Review: Pharmacology: Augmentation with pindolol
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes
 Outcome: 02 Non-responders at late assessment point




Review: Pharmacology: Augmentation with pindolol
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes
 Outcome: 03 Non-remitters at early assessment point




Review: Pharmacology: Augmentation with pindolol
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes
 Outcome: 04 Non-remitters at late assessment point




Review: Pharmacology: Augmentation with pindolol
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes
 Outcome: 05 Mean scores at early assessment point




Review: Pharmacology: Augmentation with pindolol
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes
 Outcome: 06 Mean scores at late assessment point



Review: Pharmacology: Refractory depression
 Comparison: 02 Patients with treatment resistant depression
 Outcome: 06 Augmentation with pindolol: Non-remitters at early assessment point (days 10/14)




Review: Pharmacology: Refractory depression
 Comparison: 02 Patients with treatment resistant depression
 Outcome: 07 Augmentation with pindolol: Mean score at early assessment point (day 10)




Augmentation with triiodothyronine (T3)

Review: Pharmacology: Refractory depression
 Comparison: 01 Patients whose depression has not responded to one adequate trial of an antidepressant
 Outcome: 25 Augmentation with T3: Number of people not achieving at least 50% reduction in depression



Review: Pharmacology: Refractory depression
 Comparison: 01 Patients whose depression has not responded to one adequate trial of an antidepressant
 Outcome: 26 Augmentation with T3: Mean endpoint scores




Duloxetine

Dul.01 to 02. Duloxetine versus placebo – acute phase


Dul.01.01. Acute phase: duloxetine versus placebo by dose – mean change scores

Review: Depression Update: duloxetine
 Comparison: 01 Acute phase: duloxetine vs placebo
 Outcome: 01 Mean change scores at endpoint - data for doses above licensed dose (60 mg)




Dul.01.02. Acute phase: duloxetine versus placebo – mean change scores

Review: Depression Update: duloxetine
 Comparison: 01 Acute phase: duloxetine vs placebo
 Outcome: 02 Mean change scores at endpoint - overall




DuL01.03. Acute phase: duloxetine versus placebo by dose – non-response

Review: Depression Update: duloxetine
 Comparison: 01 Acute phase: duloxetine vs placebo
 Outcome: 03 Non-response - data for doses above licensed dose (60 mg)




Dul.01.04. Acute phase: duloxetine versus placebo – non-response

Review: Depression Update: duloxetine
 Comparison: 01 Acute phase: duloxetine vs placebo
 Outcome: 04 Non-response - overall




Dul.01.05. Acute phase: duloxetine versus placebo by dose – non-remission

Review: Depression Update: duloxetine
 Comparison: 01 Acute phase: duloxetine vs placebo
 Outcome: 05 Non-remission - data for doses above licensed dose (60 mg)




Dul.01.06. Acute phase: duloxetine versus placebo – non-remission

Review: Depression Update: duloxetine
 Comparison: 01 Acute phase: duloxetine vs placebo
 Outcome: 06 Non-remission - overall




Du1.01.07. Acute phase: duloxetine versus placebo by severity – mean change scores

Review: Depression Update: duloxetine
 Comparison: 01 Acute phase: duloxetine vs placebo
 Outcome: 07 Mean change scores at endpoint (by severity)




DuL01.08. Acute phase: duloxetine versus placebo by severity – mean change scores (sensitivity analysis)

Review: Depression Update: duloxetine
 Comparison: 01 Acute phase: duloxetine vs placebo
 Outcome: 08 Sensitivity analysis: Mean change scores at endpoint (by severity)




Dul.01.09. Acute phase: duloxetine versus placebo – BPI average pain

Review: Depression Update: duloxetine
 Comparison: 01 Acute phase: duloxetine vs placebo
 Outcome: 09 Depression-related pain: BPI item 5 average pain




DuL02.01. Acute phase: duloxetine versus placebo by dose – leaving treatment early: any reason

Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 01 Leaving treatment early - any reason (data by doses above licensed dose 60mg)




Du1.02.02. Acute phase: duloxetine versus placebo – leaving treatment early: any reason

Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 02 Leaving treatment early - any reason (overall)




Dul.02.03. Acute phase: duloxetine versus placebo by dose – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 03 Leaving treatment early - adverse reactions (data by doses above licensed dose 60 mg)




DuL02.04. Acute phase: duloxetine versus placebo – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 04 Leaving treatment early - adverse reactions (overall)




Dul.02.05. Acute phase: duloxetine versus placebo by dose – leaving treatment early: lack of efficacy

Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 05 Leaving treatment early - lack of efficacy (data by doses above licensed dose 60 mg)




DuL02.06. Acute phase: duloxetine versus placebo – leaving treatment early: lack of efficacy

Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 06 Leaving treatment early - lack of efficacy (overall)




DuL02.07. Acute phase: duloxetine versus placebo – leaving treatment early: lack of efficacy (sensitivity analysis)

Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 07 Sensitivity analysis: Leaving treatment early - lack of efficacy (overall)




DuL02.08. Acute phase: duloxetine versus placebo by dose – number reporting side effects

Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 08 Number reporting side-effects (data by doses above licensed dose 60 mg)




DuL02.09. Acute phase: duloxetine versus placebo – number reporting side effects

Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 09 Number reporting side-effects (overall)




DuL02.10. Acute phase: duloxetine versus placebo by dose – mean weight change

Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 10 Mean weight change (kg) at endpoint (by doses above licensed dose 60 mg)



Dul.02.11. Acute phase: duloxetine versus placebo – mean weight change


Review: Depression Update: duloxetine
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability
 Outcome: 11 Mean weight change (kg) at endpoint (overall)



Dul.03 to 04. Duloxetine comparing different doses – acute phase


Dul.03.01. Acute phase: duloxetine comparing different doses – mean change scores

Review: Depression Update: duloxetine
 Comparison: 03 Acute phase: duloxetine at different doses
 Outcome: 01 Mean change scores at endpoint




DuL03.02. Acute phase: duloxetine comparing different doses – non-response

Review: Depression Update: duloxetine
 Comparison: 03 Acute phase: duloxetine at different doses
 Outcome: 02 Non-response




DuL03.03. Acute phase: duloxetine comparing different doses – non-remission

Review: Depression Update: duloxetine
 Comparison: 03 Acute phase: duloxetine at different doses
 Outcome: 03 Non-remission




Du1.04.01. Acute phase: duloxetine comparing different doses – leaving treatment early: any reason

Review: Depression Update: duloxetine
 Comparison: 04 Acute phase: duloxetine at different doses - acceptability and tolerability
 Outcome: 01 Leaving treatment early - any reason




Du1.04.02. Acute phase: duloxetine comparing different doses – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine
 Comparison: 04 Acute phase: duloxetine at different doses - acceptability and tolerability
 Outcome: 02 Leaving treatment early - due to adverse reaction




DuI.04.03. Acute phase: duloxetine comparing different doses – leaving treatment early: lack of efficacy

Review: Depression Update: duloxetine
 Comparison: 04 Acute phase: duloxetine at different doses - acceptability and tolerability
 Outcome: 03 Leaving treatment early - lack of efficacy




Du1.04.04. Acute phase: duloxetine comparing different doses – number reporting side effects

Review: Depression Update: duloxetine
 Comparison: 04 Acute phase: duloxetine at different doses - acceptability and tolerability
 Outcome: 04 No reporting side effects



Du1.04.05. Acute phase: duloxetine comparing different doses – mean weight change


Review: Depression Update: duloxetine
 Comparison: 04 Acute phase: duloxetine at different doses - acceptability and tolerability
 Outcome: 05 Mean weight change (kg) at endpoint



DuL05 to 06. Duloxetine versus other antidepressants – acute phase


DuL05.01. Acute phase: duloxetine versus other antidepressants – mean change scores

Review: Depression Update: duloxetine
 Comparison: 05 Acute phase: duloxetine vs other antidepressants
 Outcome: 01 Mean change scores at endpoint




Dul.05.02. Acute phase: duloxetine versus other antidepressants – non-response

Review: Depression Update: duloxetine
 Comparison: 05 Acute phase: duloxetine vs other antidepressants
 Outcome: 02 Non-response




DuI.05.03. Acute phase: duloxetine versus other antidepressants – non-remission

Review: Depression Update: duloxetine
 Comparison: 05 Acute phase: duloxetine vs other antidepressants
 Outcome: 03 Non-remission




DuL06.01. Acute phase: duloxetine versus other antidepressants – leaving treatment early: any reason

Review: Depression Update: duloxetine
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability
 Outcome: 01 Leaving treatment early - any reason




Du1.06.02. Acute phase: duloxetine versus other antidepressants – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability
 Outcome: 02 Leaving treatment early - adverse reactions




Dul.06.03. Acute phase: duloxetine versus other antidepressants – leaving treatment early: lack of efficacy

Review: Depression Update: duloxetine
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability
 Outcome: 03 Leaving treatment early - lack of efficacy




Du1.06.04. Acute phase: duloxetine versus other antidepressants – number reporting side effects

Review: Depression Update: duloxetine
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability
 Outcome: 04 Number reporting side effects




Du1.06.05. Acute phase: duloxetine versus other antidepressants – mean weight change

Review: Depression Update: duloxetine
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability
 Outcome: 05 Mean weight change (kg) at endpoint



Du1.06.06. Acute phase: duloxetine versus other antidepressants – mean weight change (sensitivity analysis)


Review: Depression Update: duloxetine
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability
 Outcome: 06 Sensitivity analysis: Mean weight change (kg) at endpoint



Dul.07. Duloxetine versus placebo – continuation phase for partial responders


Dul.07.01. Continuation phase (for partial responders): duloxetine versus placebo – mean change scores

Review: Depression Update: duloxetine
 Comparison: 07 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs placebo
 Outcome: 01 Mean change scores from end of acute phase




Dul.07.02. Continuation phase (for partial responders): duloxetine versus placebo – leaving treatment early: any reason

Review: Depression Update: duloxetine
 Comparison: 07 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs placebo
 Outcome: 02 Leaving treatment early - for any reason




DuL07.03. Continuation phase (for partial responders): duloxetine versus placebo – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine
 Comparison: 07 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs placebo
 Outcome: 03 Leaving treatment early - adverse reactions



DuL07.04. Continuation phase (for partial responders): duloxetine versus placebo – leaving treatment early: lack of efficacy


Review: Depression Update: duloxetine
 Comparison: 07 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs placebo
 Outcome: 04 Leaving treatment early - lack of efficacy



Dul.08. Duloxetine comparing different doses – continuation phase for partial responders


Dul.08.01. Continuation phase (for partial responders): duloxetine comparing different doses – mean change scores

Review: Depression Update: duloxetine
 Comparison: 08 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine at different doses
 Outcome: 01 Mean change scores from end of acute phase




Dul.08.02. Continuation phase (for partial responders): duloxetine comparing different doses – leaving treatment early: any reason

Review: Depression Update: duloxetine
 Comparison: 08 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine at different doses
 Outcome: 02 Leaving treatment early - for any reason




DuI.08.03. Continuation phase (for partial responders): duloxetine comparing different doses – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine
 Comparison: 08 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine at different doses
 Outcome: 03 Leaving treatment early - adverse reactions



DuI.08.04. Continuation phase (for partial responders): duloxetine comparing different doses – leaving treatment early: lack of efficacy


Review: Depression Update: duloxetine
 Comparison: 08 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine at different doses
 Outcome: 04 Leaving treatment early - lack of efficacy



Dul.09. Duloxetine versus other antidepressants – continuation phase for partial responders


Dul.09.01. Continuation phase (for partial responders): duloxetine versus other antidepressants – mean change scores

Review: Depression Update: duloxetine
 Comparison: 09 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs other drugs
 Outcome: 01 Mean change scores from end of acute phase




Dul.09.02. Continuation phase (for partial responders): duloxetine versus other antidepressants – leaving treatment early: any reason

Review: Depression Update: duloxetine
 Comparison: 09 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs other drugs
 Outcome: 02 Leaving treatment early - for any reason




DuI.09.03. Continuation phase (for partial responders): duloxetine versus other antidepressants – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine
 Comparison: 09 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs other drugs
 Outcome: 03 Leaving treatment early - adverse reactions



DuI.09.04. Continuation phase (for partial responders): duloxetine versus other antidepressants – leaving treatment early: lack of efficacy

Review: Depression Update: duloxetine
 Comparison: 09 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs other drugs
 Outcome: 04 Leaving treatment early - lack of efficacy




Dul.10. Duloxetine versus placebo – continuation phase for those achieving remission

No efficacy data

Dul.11. Duloxetine versus other antidepressants – continuation phase for all


Dul.11.01. Continuation phase (for all): duloxetine versus other antidepressants – mean change scores

Review: Depression Update: duloxetine
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs
 Outcome: 01 Mean scores at endpoint




Dul.11.02. Continuation phase (for all): duloxetine versus other antidepressants – non-response

Review: Depression Update: duloxetine
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs
 Outcome: 02 Non-response




Dul.11.03. Continuation phase (for all): duloxetine versus other antidepressants – non-remission

Review: Depression Update: duloxetine
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs
 Outcome: 03 Non-remission




Dul.11.04. Continuation phase (for all): duloxetine versus other antidepressants – leaving treatment early: any reason

Review: Depression Update: duloxetine
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs
 Outcome: 04 Leaving treatment early - any reason




Dul.11.05. Continuation phase (for all): duloxetine versus other antidepressants – adverse reactions

Review: Depression Update: duloxetine
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs
 Outcome: 05 Leaving treatment early - adverse reactions



Dul.11.06. Continuation phase (for all): duloxetine versus other antidepressants – lack of efficacy

Review: Depression Update: duloxetine
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs
 Outcome: 06 Leaving treatment early - lack of efficacy




Escitalopram

Esc.01. Escitalopram versus placebo


Esc.01.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 01 Escitalopram vs placebo
 Outcome: 01 Non-response




Esc.01.02. Non-remission data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 01 Escitalopram vs placebo
 Outcome: 02 Non-remission




Esc.01.03. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 01 Escitalopram vs placebo
 Outcome: 03 Mean endpoint depression scores (clinician-rated)




Esc.01.04. Mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 01 Escitalopram vs placebo
 Outcome: 04 Mean change depression scores (clinician-rated)




Esc.01.05. Number leaving treatment early for any reason

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 01 Escitalopram vs placebo
 Outcome: 05 Leaving treatment early for any reason




Esc.01.06. Number leaving treatment early due to side effects

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 01 Escitalopram vs placebo
 Outcome: 06 Leaving treatment early due to side effects



Esc.01.07. Number reporting side effects


Review: Depression Update Pharmacology: Escitalopram
 Comparison: 01 Escitalopram vs placebo
 Outcome: 07 Patients reporting side effects



Esc.02. Escitalopram versus all other antidepressants


Esc.02.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 02 Escitalopram vs all other ADs
 Outcome: 01 Non-response




Esc.02.02. Non-remission data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 02 Escitalopram vs all other ADs
 Outcome: 02 Non-remission




Esc.02.03. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 02 Escitalopram vs all other ADs
 Outcome: 03 Mean endpoint depression scores (clinician-rated)




Esc.02.04. mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 02 Escitalopram vs all other ADs
 Outcome: 04 Mean change depression scores (clinician-rated)




Esc.02.05. Number leaving treatment early for any reason

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 02 Escitalopram vs all other ADs
 Outcome: 05 Leaving treatment early for any reason




Esc.02.06. Number leaving treatment early due to side effects

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 02 Escitalopram vs all other ADs
 Outcome: 06 Leaving treatment early due to side effects



Esc.02.07. Number reporting side effects


Review: Depression Update Pharmacology: Escitalopram
 Comparison: 02 Escitalopram vs all other ADs
 Outcome: 07 Number reporting side effects



Esc.03. Escitalopram versus SSRIs


Esc.03.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 03 Escitalopram vs SSRIs
 Outcome: 01 Non-response (vs SSRIs)




Esc.03.02. Non-response data (sensitivity analysis)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 03 Escitalopram vs SSRIs
 Outcome: 02 Non-response (sensitivity analysis)




Esc.03.03. Non-remission data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 03 Escitalopram vs SSRIs
 Outcome: 03 Number not achieving remission at endpoint (vs SSRIs)




Esc.03.04. Non-remission data (sensitivity analysis)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 03 Escitalopram vs SSRIs
 Outcome: 04 Number not achieving remission at endpoint (vs SSRIs) (sensitivity analysis)




Esc.03.05. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 03 Escitalopram vs SSRIs
 Outcome: 05 Mean endpoint scores (clinician rated) (vs SSRIs)




Esc.03.06. Mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 03 Escitalopram vs SSRIs
 Outcome: 06 Mean change (clinician rated) (vs SSRIs)




Esc.03.07. Number leaving the study early for any reason

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 03 Escitalopram vs SSRIs
 Outcome: 07 Leaving the study early for any reason (vs SSRIs)




Esc.03.08. Number leaving the study early due to side effects

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 03 Escitalopram vs SSRIs
 Outcome: 08 Leaving the study early due to side effects (vs SSRIs)




Esc.03.09. Number reporting side effects

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 03 Escitalopram vs SSRIs
 Outcome: 09 Patients reporting side effects (vs SSRIs)



Esc.03.10. Number reporting side effects (sensitivity analysis)


Review: Depression Update Pharmacology: Escitalopram
 Comparison: 03 Escitalopram vs SSRIs
 Outcome: 10 Patients reporting side effects (vs SSRIs) (sensitivity analysis)



Esc.04. Escitalopram versus non-SSRIs


Esc.04.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)
 Outcome: 01 Non-response




Esc.04.02. Non-remission data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)
 Outcome: 02 Number not achieving remission at endpoint




Esc.04.03. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)
 Outcome: 03 Mean endpoint scores (clinician rated)




Esc.04.04. Mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)
 Outcome: 04 Mean change (clinician rated)




Esc.04.05. Number leaving the study early for any reason

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)
 Outcome: 05 Leaving the study early for any reason




Esc.04.06. Number leaving the study early due to side effects

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)
 Outcome: 06 Leaving the study early due to side effects



Esc.04.07. Number reporting side effects


Review: Depression Update Pharmacology: Escitalopram
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)
 Outcome: 07 Patients reporting side effects



Esc.05. Escitalopram versus all other antidepressants – citalopram separated


Esc.05.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)
 Outcome: 01 Non-response




Esc.05.02. Non-remission data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)
 Outcome: 02 Non-remission




Esc.05.03. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)
 Outcome: 03 Mean endpoint depression scores (clinician-rated)




Esc.05.04. Mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)
 Outcome: 04 Mean change scores (clinician-rated)




Esc.05.05. Number leaving treatment early for any reason

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)
 Outcome: 05 Leaving treatment early for any reason




Esc.05.06. Number leaving treatment early due to side effects

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)
 Outcome: 06 Leaving treatment early due to side effects



Esc.05.07. Number reporting side effects


Review: Depression Update Pharmacology: Escitalopram
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)
 Outcome: 07 Number reporting side effects



Esc.06. Escitalopram: overall efficacy – ordered by baseline severity


Esc.06.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 06 Overall efficacy (ordered by baseline severity)
 Outcome: 01 Number not achieving => 50% reduction in outcome score at endpoint




Esc.06.02. Non-remission data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 06 Overall efficacy (ordered by baseline severity)
 Outcome: 02 Number not achieving remission at endpoint




Esc.06.03. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 06 Overall efficacy (ordered by baseline severity)
 Outcome: 03 Mean endpoint scores (clinician rated)



Esc.06.04. Mean change depression scores (clinician-rated)


Review: Depression Update Pharmacology: Escitalopram
 Comparison: 06 Overall efficacy (ordered by baseline severity)
 Outcome: 04 Mean change (clinician rated)



Esc.07. Escitalopram: overall acceptability and tolerability – ordered by baseline severity


Esc.07.01. Number leaving the study early for any reason

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 07 Overall acceptability and tolerability (ordered by baseline severity)
 Outcome: 01 Leaving the study early for any reason




Esc.07.02. Number leaving the study early due to side effects

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 07 Overall acceptability and tolerability (ordered by baseline severity)
 Outcome: 02 Leaving the study early due to side effects



Esc.07.03. Number reporting side effects


Review: Depression Update Pharmacology: Escitalopram
 Comparison: 07 Overall acceptability and tolerability (ordered by baseline severity)
 Outcome: 03 Patients reporting side effects



Esc.08. Escitalopram: overall efficacy versus active treatment – by comparator drug


Esc.08.01. Non-response data (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)
 Outcome: 01 Number not achieving => 50% reduction in outcome score (vs SSRIs)




Esc.08.02. Non-response data (versus SSRIs) (sensitivity analysis)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)
 Outcome: 02 Number not achieving => 50% reduction in outcome score (vs SSRIs) (sensitivity analysis)




Esc.08.03. Non-response data (versus other anti-depressants)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)
 Outcome: 03 Non-response (vs other antidepressants)




Esc.08.04. Non-remission data (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)
 Outcome: 04 Number not achieving remission at endpoint (vs SSRIs)




Esc.08.05. Non-remission data (versus SSRIs) (sensitivity analysis)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)
 Outcome: 05 Number not achieving remission at endpoint (vs SSRIs) (sensitivity analysis)




Esc.08.06. Non-remission data (versus other antidepressants)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)
 Outcome: 06 Number not achieving remission at endpoint (vs other ADs)




Esc.08.07. Mean endpoint depression scores (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)
 Outcome: 07 Mean endpoint scores (clinician rated) (vs SSRIs)




Esc.08.08. Mean endpoint depression scores (clinician-rated) (versus all other antidepressants)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)
 Outcome: 08 Mean endpoint scores (clinician rated) (vs other ADs)




Esc.08.09. Mean depression change scores (clinician-rated) (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)
 Outcome: 09 Mean change (clinician rated) (vs SSRIs)



Esc.08.10. Mean depression change scores (clinician-rated) (versus all other antidepressants)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)
 Outcome: 10 Mean change (clinician rated) (vs ADs)




Esc.09. Escitalopram: overall acceptability and tolerability versus active treatment - by comparator drug

Esc.09.01. Number leaving the study early for any reason (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram


Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)

Outcome: 01 Leaving the study early for any reason (vs SSRIs)




Esc.09.02. Number leaving the study early for any reason (versus all other antidepressants)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)
 Outcome: 02 Leaving the study early for any reason (vs other ADs)




Esc.09.03. Number leaving the study early due to side effects (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)
 Outcome: 03 Leaving the study early due to side effects (vs SSRIs)




Esc.09.04. Number leaving the study early due to side effects (versus all other antidepressants)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)
 Outcome: 04 Leaving the study early due to side effects (vs other ADs)




Esc.09.05. Number reporting side effects (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)
 Outcome: 05 Patients reporting side effects (vs SSRIs)



Esc.09.06. Number reporting side effects (versus all other antidepressants)


Review: Depression Update Pharmacology: Escitalopram
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)
 Outcome: 06 Patients reporting side effects (vs other ADs)



Esc.10. Escitalopram: overall efficacy - by dose


Esc.10.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 10 Overall efficacy (by dose)
 Outcome: 01 Number not achieving =>50% reduction in outcome score at endpoint




Esc.10.02. Non-remission data

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 10 Overall efficacy (by dose)
 Outcome: 02 Number not achieving remission at endpoint




Esc.10.03. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 10 Overall efficacy (by dose)
 Outcome: 03 Mean endpoint scores (clinician rated)



Esc.10.04. Mean change depression scores (clinician-rated)


Review: Depression Update Pharmacology: Escitalopram
 Comparison: 10 Overall efficacy (by dose)
 Outcome: 04 Mean change (clinician rated)



Esc.11. Escitalopram: overall acceptability and tolerability – by dose


Esc.11.01. Number leaving the study early for any reason

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 11 Overall acceptability and tolerability (by dose)
 Outcome: 01 Leaving the study early for any reason




Esc.11.02. Number leaving the study early due to side effects

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 11 Overall acceptability and tolerability (by dose)
 Outcome: 02 Leaving the study early due to side effects




Esc.11.03. Number reporting side effects

Review: Depression Update Pharmacology: Escitalopram
 Comparison: 11 Overall acceptability and tolerability (by dose)
 Outcome: 03 Patients reporting side effects




Low dose TCAs


Review: Pharmacology: Low dose tricyclics
 Comparison: 01 Efficacy of low dose TCAs vs high dose TCAs
 Outcome: 01 Number of people not achieving remission




Review: Pharmacology: Low dose tricyclics
 Comparison: 01 Efficacy of low dose TCAs vs high dose TCAs
 Outcome: 02 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Low dose tricyclics
 Comparison: 01 Efficacy of low dose TCAs vs high dose TCAs
 Outcome: 03 Mean endpoint score




Review: Pharmacology: Low dose tricyclics
 Comparison: 02 Tolerability of low dose TCAs vs high dose TCAs
 Outcome: 01 Leaving the study early




Review: Pharmacology: Low dose tricyclics
 Comparison: 02 Tolerability of low dose TCAs v high dose TCAs
 Outcome: 02 Leaving the study early due to side effects



Review: Pharmacology: Low dose tricyclics
 Comparison: 03 Efficacy of low dose TCAs vs placebo
 Outcome: 01 Mean endpoint score




Review: Pharmacology: Low dose tricyclics
 Comparison: 03 Efficacy of low dose TCAs v placebo
 Outcome: 02 Number of people not achieving at least 50% reduction in depression score




Mirtazapine


Review: Pharmacology: Mirtazapine
 Comparison: 01 Overall efficacy
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 01 Overall efficacy
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Mirtazapine
 Comparison: 01 Overall efficacy
 Outcome: 03 Mean end point scores




Review: Pharmacology: Mirtazapine
 Comparison: 01 Overall efficacy
 Outcome: 04 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 01 Overall efficacy
 Outcome: 05 Number of inpatients not achieving remission




Review: Pharmacology: Mirtazapine
 Comparison: 01 Overall efficacy
 Outcome: 06 Mean end point scores in Inpatient studies




Review: Pharmacology: Mirtazapine
 Comparison: 01 Overall efficacy
 Outcome: 07 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 01 Overall efficacy
 Outcome: 08 Number of outpatients not achieving remission




Review: Pharmacology: Mirtazapine
 Comparison: 01 Overall efficacy
 Outcome: 09 Mean end point scores in Outpatient studies




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 01 Leaving the study early




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 04 Inpatients leaving the study early




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 05 Inpatients leaving the study early due to side effects




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 06 Inpatients reporting side effects




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 07 Outpatients leaving the study early




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 08 Outpatients leaving the study early due to side effects




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 09 Outpatients reporting side effects




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 10 Leaving the study early in primary care




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 11 Leaving the study early due to side effects in primary care




Review: Pharmacology: Mirtazapine
 Comparison: 02 Overall tolerability
 Outcome: 12 Primary care patients reporting side effects




Review: Pharmacology: Mirtazapine
 Comparison: 03 Efficacy against TCAs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 03 Efficacy against TCAs
 Outcome: 02 Mean end point scores




Review: Pharmacology: Mirtazapine
 Comparison: 03 Efficacy against TCAs
 Outcome: 04 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 03 Efficacy against TCAs
 Outcome: 05 Mean end point scores in Inpatient studies




Review: Pharmacology: Mirtazapine
 Comparison: 03 Efficacy against TCAs
 Outcome: 07 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 03 Efficacy against TCAs
 Outcome: 08 Mean end point scores in Outpatient studies




Review: Pharmacology: Mirtazapine
 Comparison: 04 Tolerability against TCAs
 Outcome: 01 Leaving the study early




Review: Pharmacology: Mirtazapine
 Comparison: 04 Tolerability against TCAs
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Mirtazapine
 Comparison: 05 Efficacy against TCAs and related ADs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 05 Efficacy against TCAs and related ADs
 Outcome: 02 Mean end point scores




Review: Pharmacology: Mirtazapine
 Comparison: 05 Efficacy against TCAs and related ADs
 Outcome: 03 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 05 Efficacy against TCAs and related ADs
 Outcome: 05 Mean end point scores in Inpatient studies




Review: Pharmacology: Mirtazapine
 Comparison: 05 Efficacy against TCAs and related ADs
 Outcome: 07 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 05 Efficacy against TCAs and related ADs
 Outcome: 08 Mean end point scores in Outpatient studies




Review: Pharmacology: Mirtazapine
 Comparison: 06 Tolerability against TCAs and related ADs
 Outcome: 01 Leaving the study early




Review: Pharmacology: Mirtazapine
 Comparison: 06 Tolerability against TCAs and related ADs
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Mirtazapine
 Comparison: 06 Tolerability against TCAs and related ADs
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Mirtazapine
 Comparison: 07 Efficacy against SSRIs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 07 Efficacy against SSRIs
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Mirtazapine
 Comparison: 07 Efficacy against SSRIs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Mirtazapine
 Comparison: 07 Efficacy against SSRIs
 Outcome: 04 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine
 Comparison: 07 Efficacy against SSRIs
 Outcome: 05 Number of outpatients not achieving remission




Review: Pharmacology: Mirtazapine
 Comparison: 07 Efficacy against SSRIs
 Outcome: 06 Mean endpoint scores in outpatient studies




Review: Pharmacology: Mirtazapine
 Comparison: 08 Tolerability against SSRIs
 Outcome: 01 Leaving the study early




Review: Pharmacology: Mirtazapine
 Comparison: 08 Tolerability against SSRIs
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Mirtazapine
 Comparison: 08 Tolerability against SSRIs
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Mirtazapine
 Comparison: 09 Efficacy at 1 or 2 weeks
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score



Review: Pharmacology: Mirtazapine
 Comparison: 09 Efficacy at 1 or 2 weeks
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Mirtazapine
 Comparison: 09 Efficacy at 1 or 2 weeks
 Outcome: 03 Mean endpoint scores




Moclobemide


Review: Pharmacology: Moclobemide
 Comparison: 01 Efficacy: Moclobemide vs antidepressants
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 01 Efficacy: Moclobemide vs antidepressants
 Outcome: 02 Sensitivity analysis: Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 01 Efficacy: Moclobemide vs antidepressants
 Outcome: 03 Non-responders




Review: Pharmacology: Moclobemide
 Comparison: 01 Efficacy: Moclobemide vs antidepressants
 Outcome: 04 Non-remitters




Review: Pharmacology: Moclobemide
 Comparison: 02 Tolerability: Moclobemide vs antidepressants
 Outcome: 01 Leaving the study early




Review: Pharmacology: Moclobemide
 Comparison: 02 Tolerability: Moclobemide vs antidepressants
 Outcome: 02 Leaving the study due to side effects




Review: Pharmacology: Moclobemide
 Comparison: 02 Tolerability: Moclobemide vs antidepressants
 Outcome: 03 Patients reporting adverse events




Review: Pharmacology: Moclobemide
 Comparison: 03 Efficacy: Moclobemide vs SSRIs
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 03 Efficacy: Moclobemide vs SSRIs
 Outcome: 02 Sensitivity analysis: Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 03 Efficacy: Moclobemide vs SSRIs
 Outcome: 03 Non-responders




Review: Pharmacology: Moclobemide
 Comparison: 03 Efficacy: Moclobemide v SSRIs
 Outcome: 04 Non-remitters




Review: Pharmacology: Moclobemide
 Comparison: 04 Tolerability: Moclobemide vs SSRIs
 Outcome: 01 Leaving the study early




Review: Pharmacology: Moclobemide
 Comparison: 04 Tolerability: Moclobemide vs SSRIs
 Outcome: 02 Leaving the study due to side effects




Review: Pharmacology: Moclobemide
 Comparison: 04 Tolerability: Moclobemide vs SSRIs
 Outcome: 03 Patients reporting adverse events




Review: Pharmacology: Moclobemide
 Comparison: 05 Efficacy: Moclobemide vs TCAs
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 05 Efficacy: Moclobemide vs TCAs
 Outcome: 02 Sensitivity analysis: Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 05 Efficacy: Moclobemide vs TCAs
 Outcome: 03 Non-responders




Review: Pharmacology: Moclobemide
 Comparison: 05 Efficacy: Moclobemide vs TCAs
 Outcome: 04 Non-remitters




Review: Pharmacology: Moclobemide
 Comparison: 06 Tolerability: Moclobemide vs TCAs
 Outcome: 01 Leaving the study early




Review: Pharmacology: Moclobemide
 Comparison: 06 Tolerability: Moclobemide vs TCAs
 Outcome: 02 Leaving the study due to side effects




Review: Pharmacology: Moclobemide
 Comparison: 06 Tolerability: Moclobemide vs TCAs
 Outcome: 03 Patients reporting adverse events




Review: Pharmacology: Moclobemide
 Comparison: 07 Inpatients: Moclobemide vs antidepressants
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 07 Inpatients: Moclobemide vs antidepressants
 Outcome: 02 Sensitivity analysis: Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 07 Inpatients: Moclobemide vs antidepressants
 Outcome: 03 Non-responders




Review: Pharmacology: Moclobemide
 Comparison: 07 Inpatients: Moclobemide vs antidepressants
 Outcome: 04 Leaving the study early




Review: Pharmacology: Moclobemide
 Comparison: 07 Inpatients: Moclobemide vs antidepressants
 Outcome: 05 Leaving the study due to side effects




Review: Pharmacology: Moclobemide
 Comparison: 07 Inpatients: Moclobemide vs antidepressants
 Outcome: 06 Patients reporting adverse events




Review: Pharmacology: Moclobemide
 Comparison: 08 Outpatients: Moclobemide vs antidepressants
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 08 Outpatients: Moclobemide vs antidepressants
 Outcome: 02 Sensitivity analysis: Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 08 Outpatients: Moclobemide vs antidepressants
 Outcome: 03 Non-responders




Review: Pharmacology: Moclobemide
 Comparison: 08 Outpatients: Moclobemide vs antidepressants
 Outcome: 04 Non-remitters




Review: Pharmacology: Moclobemide
 Comparison: 08 Outpatients: Moclobemide vs antidepressants
 Outcome: 05 Leaving the study early




Review: Pharmacology: Moclobemide
 Comparison: 08 Outpatients: Moclobemide vs antidepressants
 Outcome: 06 Leaving the study due to side effects




Review: Pharmacology: Moclobemide
 Comparison: 08 Outpatients: Moclobemide vs antidepressants
 Outcome: 07 Patients reporting adverse events




Review: Pharmacology: Moclobemide
 Comparison: 09 Primary care patients: Moclobemide vs antidepressants
 Outcome: 01 Non-responders




Review: Pharmacology: Moclobemide
 Comparison: 09 Primary care patients: Moclobemide vs antidepressants
 Outcome: 02 Non-remitters




Review: Pharmacology: Moclobemide
 Comparison: 09 Primary care patients: Moclobemide vs antidepressants
 Outcome: 03 Leaving the study early




Review: Pharmacology: Moclobemide
 Comparison: 09 Primary care patients: Moclobemide vs antidepressants
 Outcome: 04 Leaving the study due to side effects




Review: Pharmacology: Moclobemide
 Comparison: 09 Primary care patients: Moclobemide vs antidepressants
 Outcome: 05 Patients reporting adverse events




Review: Pharmacology: Moclobemide
 Comparison: 10 Efficacy: Moclobemide vs placebo
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide
 Comparison: 10 Efficacy: Moclobemide vs placebo
 Outcome: 02 Non-responders




Review: Pharmacology: Moclobemide
 Comparison: 10 Efficacy: Moclobemide vs placebo
 Outcome: 03 Non-remitters




Review: Pharmacology: Moclobemide
 Comparison: 11 Tolerability: Moclobemide vs placebo
 Outcome: 01 Leaving the study early



Review: Pharmacology: Moclobemide
 Comparison: 11 Tolerability: Moclobemide vs placebo
 Outcome: 02 Leaving the study due to side effects



Review: Pharmacology: Moclobemide
 Comparison: 11 Tolerability: Moclobemide vs placebo
 Outcome: 03 Patients reporting adverse events




Next-step treatments

Next step 01. Dose escalation


Next-step 01.01. Dose escalation – mean depression scores

Review: Depression update: pharmacology – next-step treatments
 Comparison: 01 Dose escalation
 Outcome: 01 Mean depression scores




Next-step 01.02. Dose escalation – number not achieving remission

Review: Depression update: pharmacology – next-step treatments
 Comparison: 01 Dose escalation
 Outcome: 02 Number not achieving remission



Next-step 01.03. Dose escalation – number not achieving response

Review: Depression update: pharmacology – next-step treatments
 Comparison: 01 Dose escalation
 Outcome: 03 Number not achieving response




Next-step 01.04. Dose escalation – leaving treatment early for any reason

Review: Depression update: pharmacology – next-step treatments

Comparison: 01 Dose escalation

Outcome: 04 Leaving treatment early for any reason




Next-step 01.05. Dose escalation – leaving treatment early due to side effects

Review: Depression update: pharmacology – next-step treatments


Comparison: 01 Dose escalation

Outcome: 05 Leaving treatment early due to side effects




Next-step 01.06. Dose escalation – leaving treatment early due to lack of efficacy

Review: Depression update: pharmacology – next-step treatments
 Comparison: 01 Dose escalation
 Outcome: 06 Leaving treatment early due to lack of efficacy



Next-step 01.07. Dose escalation – number reporting side effects

Review: Depression update: pharmacology – next-step treatments
 Comparison: 01 Dose escalation
 Outcome: 07 Number reporting side effects




Next-step switching

Next-step 02. Switching: continuing antidepressants versus switching


Next-step 02.01. Switching: continuing antidepressants versus switching – number not achieving response

Review: Depression update: pharmacology – next-step treatments
 Comparison: 02 Switching: continuing AD vs switching
 Outcome: 01 Number not achieving response




Next-step 02.02. Switching: continuing antidepressants versus switching – number not achieving remission

Review: Depression update: pharmacology – next-step treatments
 Comparison: 02 Switching: continuing AD vs switching
 Outcome: 02 Number not achieving remission




Next-step 02.03. Switching: continuing antidepressants versus switching – mean endpoint scores (self-rated)

Review: Depression update: pharmacology – next-step treatments
 Comparison: 02 Switching: continuing AD vs switching
 Outcome: 03 Other comparisons: mean endpoint scores (self-rated)




Next-step 02.04. Switching: continuing antidepressants versus switching – leaving treatment early for any reason

Review: Depression update: pharmacology – next-step treatments
 Comparison: 02 Switching: continuing AD vs switching
 Outcome: 04 Other comparisons: number leaving treatment early for any reason




Next-step 02.05. Switching: continuing antidepressants versus switching – leaving treatment early because of side effects

Review: Depression update: pharmacology – next-step treatments
 Comparison: 02 Switching: continuing AD vs switching
 Outcome: 05 Other comparisons: number leaving treatment early because of side effects



Next-step 02.06. Switching: continuing antidepressants versus switching – number reporting side effects


Review: Depression update: pharmacology – next-step treatments
 Comparison: 02 Switching: continuing AD vs switching
 Outcome: 06 Other comparisons: number reporting side effects



Next-step 03. Switching: switching to single or combination drugs


Next-step 03.01. Switching: switching to venlafaxine versus switch to another drug – efficacy data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 03 Switching: switching to single or combination drugs
 Outcome: 01 Switch to venlafaxine vs switch to another antidepressant (efficacy)




Next-step 03.02. Switching: switching to venlafaxine versus switch to another drug – efficacy data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 03 Switching: switching to single or combination drugs
 Outcome: 02 Switch to venlafaxine vs switch to another antidepressant (efficacy)




Next-step 03.03. Switching: switching to venlafaxine versus switch to another drug – acceptability/tolerability data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 03 Switching: switching to single or combination drugs
 Outcome: 03 Switch to venlafaxine vs switch to another antidepressant (acceptability/tolerability)




Next-step 03.04. Switching: switching to fluoxetine versus olanzapine – efficacy data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 03 Switching: switching to single or combination drugs
 Outcome: 04 Switch to fluoxetine vs switch to olanzapine (efficacy)




Next-step 03.05. Switching: switching to fluoxetine versus olanzapine – efficacy data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 03 Switching: switching to single or combination drugs
 Outcome: 05 Switch to fluoxetine vs switch to olanzapine (efficacy)




Next-step 03.06. Switching: switching to fluoxetine versus olanzapine – acceptability/tolerability data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 03 Switching: switching to single or combination drugs
 Outcome: 06 Switch to fluoxetine vs switch to olanzapine (acceptability/tolerability)




Next-step 03.07. Switching: switching to augmentation strategy versus switch to single drug – efficacy data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 03 Switching: switching to single or combination drugs
 Outcome: 07 Switch to augmentation strategy vs switch to single drug: efficacy outcomes




Next-step 03.08. Switching: switching to augmentation strategy versus switch to single drug – efficacy data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 03 Switching: switching to single or combination drugs
 Outcome: 08 Switch to augmentation strategy vs switch to single drug: efficacy outcomes



Next-step 03.09. Switching: switching to augmentation strategy versus switch to single drug – acceptability/tolerability data


Review: Depression update: pharmacology – next-step treatments
 Comparison: 03 Switching: switching to single or combination drugs
 Outcome: 09 Switch to augmentation strategy vs switch to single drug: acceptability/tolerability



Next-step 04. Switching to a single drug


Next-step 04.01. Switching: switching to single drug (randomised first step) – non-response

Review: Depression update: pharmacology – next-step treatments
 Comparison: 04 Switching: switching to single drug (randomised first-step drug)
 Outcome: 01 Switching strategies: Number of people not achieving at least 50% reduction in depression score




Next-step 04.02. Switching: switching to single drug (randomised first step) – mean endpoint data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 04 Switching: switching to single drug (randomised first-step drug)
 Outcome: 02 Switching strategies: Mean endpoint scores



Next-step 04.03. Switching: switching to single drug (randomised first step) – leaving treatment early


Review: Depression update: pharmacology – next-step treatments
 Comparison: 04 Switching: switching to single drug (randomised first-step drug)
 Outcome: 03 Switching strategies: Leaving the study early



Next-step 05. Switching: single antidepressants versus augmentation strategy


Next-step 05.01. Switching: single antidepressants versus augmentation strategy – non-remission

Review: Depression update: pharmacology – next-step treatments
 Comparison: 05 Switching: single AD vs augmentation strategy (open-label data)
 Outcome: 01 Number not achieving remission




Next-step 05.02. Switching: single antidepressants versus augmentation strategy – mean endpoint data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 05 Switching: single AD vs augmentation strategy (open-label data)
 Outcome: 02 Mean endpoint scores (self-rated)




Next-step 05.03. Switching: single antidepressants versus augmentation strategy – leaving treatment early for any reason

Review: Depression update: pharmacology – next-step treatments
 Comparison: 05 Switching: single AD vs augmentation strategy (open-label data)
 Outcome: 03 Number leaving treatment early for any reason



Next-step 05.04. Switching: single antidepressants versus augmentation strategy – leaving treatment early due to side effects


Review: Depression update: pharmacology – next-step treatments
 Comparison: 05 Switching: single AD vs augmentation strategy (open-label data)
 Outcome: 04 Number leaving treatment early because of side effects



Next-step 06. Switching: single antidepressants (open-label data)


Next-step 06.01. Switching: single antidepressants (open-label data) – non-remission

Review: Depression update: pharmacology – next-step treatments
 Comparison: 06 Switching: switching to single drug (open-label data)
 Outcome: 01 Number not achieving remission




Next-step 06.02. Switching: single antidepressants (open-label data) – mean endpoint data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 06 Switching: switching to single drug (open-label data)
 Outcome: 02 Mean endpoint data




Next-step 06.03. Switching: single antidepressants (open-label data) – leaving treatment early for any reason

Review: Depression update: pharmacology – next-step treatments
 Comparison: 06 Switching: switching to single drug (open-label data)
 Outcome: 03 Leaving the study early for any reason




Next-step 06.04. Switching: single antidepressants (open-label data) – leaving treatment early due to side effects

Review: Depression update: pharmacology – next-step treatments
 Comparison: 06 Switching: switching to single drug (open-label data)
 Outcome: 04 Leaving the study early due to side effects



Next-step 06.05. Switching: single antidepressants (open-label data) – number reporting side effects


Review: Depression update: pharmacology – next-step treatments
 Comparison: 06 Switching: switching to single drug (open-label data)
 Outcome: 05 Number reporting side effects



Next-step 07. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing)


Next-step 07.01. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – non-response

Review: Depression update: pharmacology – next-step treatments
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)
 Outcome: 01 Number not achieving response




Next-step 07.02. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – non-remission

Review: Depression update: pharmacology – next-step treatments
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)
 Outcome: 02 Number not achieving remission




Next-step 07.03. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – mean endpoint or change scores

Review: Depression update: pharmacology – next-step treatments
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)
 Outcome: 03 Mean endpoint or change scores




Next-step 07.04. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – leaving treatment early for any reason

Review: Depression update: pharmacology – next-step treatments
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)
 Outcome: 04 Leaving the study early




Next-step 07.05. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – leaving treatment early due to side effects

Review: Depression update: pharmacology – next-step treatments
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)
 Outcome: 05 Leaving the study early due to side effects



Next-step 07.06. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – patients reporting side effects


Review: Depression update: pharmacology – next-step treatments
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)
 Outcome: 06 Patients reporting side effects



Next-step 08. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing)


Next-step 08.01. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – non-response

Review: Depression update: pharmacology – next-step treatments
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)
 Outcome: 01 Number not achieving response




Next-step 08.02. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – non-remission

Review: Depression update: pharmacology – next-step treatments
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)
 Outcome: 02 Number not achieving remission




Next-step 08.03. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – mean endpoint

Review: Depression update: pharmacology – next-step treatments
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)
 Outcome: 03 Mean endpoint




Next-step 08.04. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – number leaving treatment early for any reason

Review: Depression update: pharmacology – next-step treatments
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)
 Outcome: 04 Number leaving treatment early for any reason




Next-step 08.05. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – number leaving treatment early due to side effects

Review: Depression update: pharmacology – next-step treatments
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)
 Outcome: 05 Number leaving treatment early due to side effects



Next-step 08.06. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – number reporting side effects


Review: Depression update: pharmacology – next-step treatments
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)
 Outcome: 06 Number reporting side effects



Next-step 09. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing)


Next-step 09.01. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing) – non-response

Review: Depression update: pharmacology – next-step treatments
 Comparison: 09 Augmentation: AD + other psychotropic drug vs AD + (placebo or nothing)
 Outcome: 01 Number not achieving response




Next-step 09.02. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing) – non-remission

Review: Depression update: pharmacology – next-step treatments
 Comparison: 09 Augmentation: AD + other psychotropic drug vs AD + (placebo or nothing)
 Outcome: 02 Number not achieving remission




Next-step 09.03. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing) – mean endpoint change scores

Review: Depression update: pharmacology – next-step treatments
 Comparison: 09 Augmentation: AD + other psychotropic drug vs AD + (placebo or nothing)
 Outcome: 03 Mean endpoint or change scores




Next-step 09.04. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing) – leaving treatment early for any reason

Review: Depression update: pharmacology – next-step treatments
 Comparison: 09 Augmentation: AD + other psychotropic drug vs AD + (placebo or nothing)
 Outcome: 04 Leaving the study early



Next-step 09.05. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing) – leaving treatment early due to side effects


Review: Depression update: pharmacology – next-step treatments
 Comparison: 09 Augmentation: AD + other psychotropic drug vs AD + (placebo or nothing)
 Outcome: 05 Leaving the study early due to side effects



Next-step 10. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug - open-label data


Next-step 10.01. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug (open-label data) – non-remission

Review: Depression update: pharmacology – next-step treatments
 Comparison: 10 Augmentation: AD + other psychotropic drug vs AD + other psychotropic drug (open-label data)
 Outcome: 01 Number not achieving remission




Next-step 10.02. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug (open-label data) – mean endpoint (self-rated)

Review: Depression update: pharmacology – next-step treatments
 Comparison: 10 Augmentation: AD + other psychotropic drug vs AD + other psychotropic drug (open-label data)
 Outcome: 02 Mean endpoint scores (self-rated)




Next-step 10.03. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug (open-label data) – leaving treatment early for any reason

Review: Depression update: pharmacology – next-step treatments
 Comparison: 10 Augmentation: AD + other psychotropic drug vs AD + other psychotropic drug (open-label data)
 Outcome: 03 Number leaving treatment early for any reason




Next-step 10.04. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug (open-label data) – leaving treatment early due to side effects

Review: Depression update: pharmacology – next-step treatments
 Comparison: 10 Augmentation: AD + other psychotropic drug vs AD + other psychotropic drug (open-label data)
 Outcome: 04 Number leaving treatment early due to side effects



Next-step 10.05. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug (open-label data) – number reporting side effects


Review: Depression update: pharmacology – next-step treatments
 Comparison: 10 Augmentation: AD + other psychotropic drug vs AD + other psychotropic drug (open-label data)
 Outcome: 05 Number reporting side effects



Next-step 11. Comparisons involving CBT – open-label data


Next-step 11.01. Switch to CBT versus single antidepressant (open-label data) – all available dichotomous data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 11 Comparisons involving CBT (open-label data)
 Outcome: 01 Switch to CBT or single antidepressant




Next-step 11.02. Switch to CBT versus single antidepressant – all available continuous data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 11 Comparisons involving CBT (open-label data)
 Outcome: 02 Switch to CBT vs single antidepressant




Next-step 11.03. Augmentation: antidepressant + CBT versus antidepressant + bupropion or buspirone (open-label data) – all available dichotomous data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 11 Comparisons involving CBT (open-label data)
 Outcome: 03 Augmentation: AD + CBT vs AD + bupripion or buspirone



Next-step 11.04. Augmentation: antidepressant + CBT versus antidepressant + bupropion or buspirone (open-label data) – all available continuous data


Review: Depression update: pharmacology – next-step treatments
 Comparison: 11 Comparisons involving CBT (open-label data)
 Outcome: 04 Augmentation: AD + CBT vs AD + bupripion or buspirone



Next-step 12. Electroconvulsive therapy (ECT)


Next-step 12.01. ECT: bilateral versus unilateral – all dichotomous data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 12 Comparisons involving ECT
 Outcome: 01 Bilateral ECT vs unilateral ECT (basic comparisons - all outcomes)




Next-step 12.02. ECT: bilateral versus unilateral – all continuous data

Review: Depression update: pharmacology – next-step treatments
 Comparison: 12 Comparisons involving ECT
 Outcome: 02 Bilateral ECT vs unilateral ECT (basic comparisons - all data)




Next-step 12.03. ECT: bilateral versus unilateral: same dose comparison – non-response

Review: Depression update: pharmacology – next-step treatments
 Comparison: 12 Comparisons involving ECT
 Outcome: 03 Bilateral ECT vs unilateral ECT (same dose) - number of non-responders




Next-step 12.04. ECT: low-dose bilateral versus low-dose unilateral – non-response

Review: Depression update: pharmacology – next-step treatments
 Comparison: 12 Comparisons involving ECT
 Outcome: 04 Low-dose bilateral ECT vs low-dose unilateral ECT - non-responders




Next-step 12.05. ECT: low-dose bilateral versus low-dose unilateral – non-remission

Review: Depression update: pharmacology – next-step treatments
 Comparison: 12 Comparisons involving ECT
 Outcome: 05 Low-dose bilateral ECT vs low-dose unilateral ECT - non-remission




Next-step 12.06. ECT: low-dose bilateral versus low-dose unilateral – mean endpoint

Review: Depression update: pharmacology – next-step treatments
 Comparison: 12 Comparisons involving ECT
 Outcome: 06 Low-dose bilateral vs low-dose unilateral - mean endpoint depression scores




Next-step 12.07. ECT: low-dose bilateral versus high-dose unilateral – non-response

Review: Depression update: pharmacology – next-step treatments
 Comparison: 12 Comparisons involving ECT
 Outcome: 07 Low-dose bilateral ECT vs high-dose unilateral ECT - non-responders




Next-step 12.08. ECT: low-dose bilateral versus high-dose unilateral – non-remission

Review: Depression update: pharmacology – next-step treatments
 Comparison: 12 Comparisons involving ECT
 Outcome: 08 Low-dose bilateral ECT vs high-dose unilateral ECT - non-remission




Next-step 12.09. ECT: low-dose bilateral versus high-dose unilateral – mean endpoint

Review: Depression update: pharmacology – next-step treatments
 Comparison: 12 Comparisons involving ECT
 Outcome: 09 Bilateral ECT (low dose) vs high-dose unilateral ECT - mean endpoint scores




Older adults sub-analyses


Review: Pharmacology: Older adults sub-analysis
 Comparison: 01 Amitriptyline: Overall efficacy in older adults
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis
 Comparison: 01 Amitriptyline: Overall efficacy in older adults
 Outcome: 02 Mean endpoint scores




Review: Pharmacology: Older adults sub-analysis
 Comparison: 01 Amitriptyline: Overall efficacy in older adults
 Outcome: 03 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis
 Comparison: 01 Amitriptyline: Overall efficacy in older adults
 Outcome: 04 Mean endpoint scores in inpatients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 01 Amitriptyline: Overall efficacy in older adults
 Outcome: 08 Number of primary care patients not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis
 Comparison: 01 Amitriptyline: Overall efficacy in older adults
 Outcome: 09 Mean endpoint scores in primary care patients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 03 Patients with side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 04 Leaving the study early in inpatients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 05 Leaving the study early due to side effects in inpatients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 06 Inpatients with side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 07 Leaving the study early in outpatients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 08 Leaving the study early due to side effects in outpatients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 10 Leaving the study early in primary care patients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 11 Leaving the study early due to side effects in primary care patients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 02 Amitriptyline: Overall tolerability in older adults
 Outcome: 12 Patients in primary care with side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 03 SSRIs versus alternative antidepressants in older adults
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Older adults sub-analysis
 Comparison: 03 SSRIs versus alternative antidepressants in older adults
 Outcome: 02 Mean endpoint scores in Inpatients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 03 SSRIs versus alternative antidepressants in older adults
 Outcome: 03 Mean endpoint scores outpatients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 03 SSRIs versus alternative antidepressants in older adults
 Outcome: 04 Mean endpoint scores in Primary Care




Review: Pharmacology: Older adults sub-analysis
 Comparison: 03 SSRIs versus alternative antidepressants in older adults
 Outcome: 05 Leaving the study early




Review: Pharmacology: Older adults sub-analysis
 Comparison: 03 SSRIs versus alternative antidepressants in older adults
 Outcome: 06 Leaving the study due to side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 03 SSRIs versus alternative antidepressants in older adults
 Outcome: 07 Patients reporting adverse events




Review: Pharmacology: Older adults sub-analysis
 Comparison: 04 Venlafaxine: Efficacy in older adults
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis
 Comparison: 04 Venlafaxine: Efficacy in older adults
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Older adults sub-analysis
 Comparison: 05 Venlafaxine: Tolerability in older adults
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis
 Comparison: 05 Venlafaxine: Tolerability in older adults
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 05 Venlafaxine: Tolerability in older adults
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 06 Mirtazapine: Overall efficacy in older adults
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis
 Comparison: 06 Mirtazapine: Overall efficacy in older adults
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Older adults sub-analysis
 Comparison: 06 Mirtazapine: Overall efficacy in older adults
 Outcome: 03 Mean end point scores




Review: Pharmacology: Older adults sub-analysis
 Comparison: 07 Mirtazapine: Overall tolerability in older adults
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis
 Comparison: 07 Mirtazapine: Overall tolerability in older adults
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 07 Mirtazapine: Overall tolerability in older adults
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 08 Phenelzine: Overall efficacy in older adults
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Older adults sub-analysis
 Comparison: 09 Phenelzine: Overall tolerability in older adults
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis
 Comparison: 09 Phenelzine: Overall tolerability in older adults
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 09 Phenelzine: Overall tolerability in older adults
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Older adults sub-analysis
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Older adults sub-analysis
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults
 Outcome: 05 Mean endpoint scores in inpatients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults
 Outcome: 07 Number of outpatients not achieving remission




Review: Pharmacology: Older adults sub-analysis
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults
 Outcome: 09 Mean endpoint scores in outpatients




Review: Pharmacology: Older adults sub-analysis
 Comparison: 11 TCAs against alternative antidepressants: Tolerability in older adults
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis
 Comparison: 11 TCAs against alternative antidepressants: Tolerability in older adults
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 11 TCAs against alternative antidepressants: Tolerability in older adults
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 12 Lithium augmentation: Overall efficacy in older adults
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Older adults sub-analysis
 Comparison: 13 Lithium augmentation: Overall tolerability in older adults
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis
 Comparison: 13 Lithium augmentation: Overall tolerability in older adults
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 14 St John's wort: Efficacy in older adults
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis
 Comparison: 14 St John's wort: Efficacy in older adults
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Older adults sub-analysis
 Comparison: 15 St John's wort: Tolerability in older adults
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis
 Comparison: 15 St John's wort: Tolerability in older adults
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 15 St John's wort: Tolerability in older adults
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Older adults sub-analysis
 Comparison: 16 Relapse prevention for older adults
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Older adults sub-analysis
 Comparison: 16 Relapse prevention for older adults
 Outcome: 02 Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Older adults sub-analysis
 Comparison: 16 Relapse prevention for older adults
 Outcome: 03 Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Older adults sub-analysis
 Comparison: 16 Relapse prevention for older adults
 Outcome: 04 SSRIs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Older adults sub-analysis
 Comparison: 16 Relapse prevention for older adults
 Outcome: 05 SSRIs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Older adults sub-analysis
 Comparison: 16 Relapse prevention for older adults
 Outcome: 06 SSRIs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Older adults sub-analysis
 Comparison: 16 Relapse prevention for older adults
 Outcome: 07 TCAs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Older adults sub-analysis
 Comparison: 16 Relapse prevention for older adults
 Outcome: 08 TCAs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Older adults sub-analysis
 Comparison: 16 Relapse prevention for older adults
 Outcome: 09 TCAs: Number of patients with relapse of depression (2x2 analysis)



Review: Pharmacology: Older adults sub-analysis
 Comparison: 17 Antidepressant + antipsychotic vs control in older adults
 Outcome: 01 Number of people not achieving remission




Review: Pharmacology: Older adults sub-analysis
 Comparison: 17 Antidepressant + antipsychotic vs control in older adults
 Outcome: 02 Mean endpoint scores




Phenelzine


Review: Pharmacology: Phenelzine
 Comparison: 01 Overall efficacy
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Phenelzine
 Comparison: 01 Overall efficacy
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Phenezine
 Comparison: 01 Overall efficacy
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Phenzelzine
 Comparison: 02 Overall tolerability
 Outcome: 01 Leaving the study early




Review: Pharmacology: Phenelzine
 Comparison: 02 Overall tolerability
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Phenelzine
 Comparison: 02 Overall tolerability
 Outcome: 03 Patients reporting adverse effects




Review: Pharmacology: Phenelzine
 Comparison: 03 Overall efficacy against SSRIs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Phenzine
 Comparison: 03 Overall efficacy against SSRIs
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Phenzine
 Comparison: 03 Overall efficacy against SSRIs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Phenelzine
 Comparison: 04 Overall tolerability against SSRIs
 Outcome: 01 Leaving the study early




Review: Pharmacology: Phenelzine
 Comparison: 04 Overall tolerability against SSRIs
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Phenelzine
 Comparison: 05 Overall efficacy against TCAs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Phenelzine
 Comparison: 05 Overall efficacy against TCAs
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Phenelzine
 Comparison: 05 Overall efficacy against TCAs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Phenzelzine
 Comparison: 06 Overall tolerability against TCAs
 Outcome: 01 Leaving the study early



Review: Pharmacology: Phenzelzine
 Comparison: 06 Overall tolerability against TCAs
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Phenezine
 Comparison: 06 Overall tolerability against TCAs
 Outcome: 03 Patients reporting adverse effects




Depression with psychotic features


Review: Pharmacology: Psychotic depression
 Comparison: 01 Antidepressant + antipsychotic vs control (<15% bipolar patients)
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Psychotic depression
 Comparison: 01 Antidepressant + antipsychotic vs control (< 15% bipolar patients)
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Psychotic depression
 Comparison: 01 Antidepressant + antipsychotic vs control (<15% bipolar patients)
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Psychotic depression
 Comparison: 01 Antidepressant + antipsychotic vs control (<15% bipolar patients)
 Outcome: 04 Leaving the study early




Review: Pharmacology: Psychotic depression
 Comparison: 02 Antidepressant vs antidepressant (<15% bipolar patients)
 Outcome: 01 Number of people not achieving remission




Review: Pharmacology: Psychotic depression
 Comparison: 02 Antidepressant vs antidepressant (<15% bipolar patients)
 Outcome: 02 Leaving the study early




Review: Pharmacology: Psychotic depression
 Comparison: 02 Antidepressant vs antidepressant (<15% bipolar patients)
 Outcome: 03 Leaving the study early due to side effects




Review: Pharmacology: Psychotic depression
 Comparison: 03 Antidepressant + antipsychotic vs control (<25% bipolar patients)
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Psychotic depression
 Comparison: 03 Antidepressant + antipsychotic vs control (<25% bipolar patients)
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Psychotic depression
 Comparison: 03 Antidepressant + antipsychotic vs control (<25% bipolar patients)
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Psychotic depression
 Comparison: 03 Antidepressant + antipsychotic vs control (<25% bipolar patients)
 Outcome: 04 Leaving the study early




Review: Pharmacology: Psychotic depression
 Comparison: 04 Antidepressant vs antidepressant (<25% bipolar patients)
 Outcome: 01 Number of people not achieving remission



Review: Pharmacology: Psychotic depression
 Comparison: 04 Antidepressant vs antidepressant (<25% bipolar patients)
 Outcome: 02 Leaving the study early




Review: Pharmacology: Psychotic depression
 Comparison: 04 Antidepressant vs antidepressant (<25% bipolar patients)
 Outcome: 03 Leaving the study early due to side effects




Reboxetine


Review: Pharmacology: Reboxetine
 Comparison: 01 Efficacy against other ADs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Reboxetine
 Comparison: 01 Efficacy against other ADs
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Reboxetine
 Comparison: 01 Efficacy against other ADs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Reboxetine
 Comparison: 02 Tolerability against other ADs
 Outcome: 01 Leaving the study early




Review: Pharmacology: Reboxetine
 Comparison: 02 Tolerability against other ADs
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Reboxetine
 Comparison: 02 Tolerability against other ADs
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Reboxetine
 Comparison: 03 Efficacy against placebo
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Reboxetine
 Comparison: 03 Efficacy against placebo
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Reboxetine
 Comparison: 04 Tolerability against placebo
 Outcome: 01 Leaving the study early



Review: Pharmacology: Reboxetine
 Comparison: 04 Tolerability against placebo
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Reboxetine
 Comparison: 04 Tolerability against placebo
 Outcome: 03 Patients reporting side effects




Relapse prevention

Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 02 Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 03 Number of patients with relapse of depression (2x2 analysis)

Study or sub-category	Treatment n/N	Control n/N	RD (random) 95% CI	Weight %	RD (random) 95% CI	Order
01 <6 months treatment prior to randomisation / <12 months of randomised treatment						
Doogan1992 Y O C	12/185	33/110		4.56	-0.24 [-0.33, -0.14]	0
Feiger1999 Y O C	1/65	9/66		4.68	-0.12 [-0.21, -0.03]	0
GORWOOD2007 E O	13/152	50/153		4.71	-0.24 [-0.33, -0.15]	0
Hochstrasser2001 YMC	24/132	59/137		4.22	-0.25 [-0.35, -0.14]	0
Klysner2002 E O C	19/60	41/61		2.88	-0.36 [-0.52, -0.19]	0
Montgomery1992 Y M C	11/105	13/42		3.17	-0.20 [-0.36, -0.05]	0
PERAHIA2006B Y O	62/136	95/142		4.02	-0.21 [-0.33, -0.10]	0
RAPAPORT2004 Y ?	31/181	22/93		4.31	-0.07 [-0.17, 0.04]	0
Robert1995 Y O C	21/152	18/74		4.06	-0.11 [-0.22, 0.01]	0
Robinson1991 Y O C	9/31	13/16		1.73	-0.52 [-0.77, -0.27]	0
Sackeim2001 Y ? S	15/27	21/29		1.74	-0.17 [-0.42, 0.08]	0
Schmidt2000 Y O C	49/189	61/122		4.15	-0.24 [-0.35, -0.13]	0
Thase2001 Y ? C	15/77	34/84		3.47	-0.21 [-0.35, -0.07]	0
VANdenBROEK2006 YI	2/12	12/15		1.36	-0.63 [-0.93, -0.34]	0
Versiani1999 Y M C	29/145	74/141		4.24	-0.32 [-0.43, -0.22]	0
Subtotal (95% CI)	1649	1285		53.29	-0.23 [-0.28, -0.18]	
Total events: 313 (Treatment), 555 (Control)						
Test for heterogeneity: Chi ² = 38.67, df = 14 (P = 0.0004), I ² = 63.8%						
Test for overall effect: Z = 8.40 (P < 0.00001)						
02 <6 months treatment prior to randomisation / >=12 months of randomised treatment						
Alexopoulos2000 EOC	4/22	11/21		1.56	-0.34 [-0.61, -0.07]	0
Kishimoto1994 Y O S	4/12	13/14		1.32	-0.60 [-0.89, -0.30]	0
MCGRATH2006 Y ?	60/131	94/131		3.99	-0.26 [-0.37, -0.14]	0
Montgomery1988 ? O C	23/108	54/112		3.86	-0.27 [-0.39, -0.15]	0
Montgomery1993 Y M C	10/68	27/67		3.31	-0.26 [-0.40, -0.11]	0
Prien1984 Y M S	13/40	22/34		2.10	-0.32 [-0.54, -0.11]	0
Terra1998 Y O C	14/110	33/94		4.00	-0.22 [-0.34, -0.11]	0
Subtotal (95% CI)	491	473		20.13	-0.27 [-0.33, -0.22]	
Total events: 128 (Treatment), 254 (Control)						
Test for heterogeneity: Chi ² = 5.73, df = 6 (P = 0.45), I ² = 0%						
Test for overall effect: Z = 9.47 (P < 0.00001)						
03 >=6 months treatment prior to randomisation / <12 months of randomised treatment						
Cook1986 E O C	0/7	3/9		1.07	-0.33 [-0.67, 0.01]	0
Gilaberte2001 Y O C	14/70	28/70		3.24	-0.20 [-0.35, -0.05]	0
Subtotal (95% CI)	77	79		4.31	-0.22 [-0.36, -0.09]	
Total events: 14 (Treatment), 31 (Control)						
Test for heterogeneity: Chi ² = 0.51, df = 1 (P = 0.48), I ² = 0%						
Test for overall effect: Z = 3.19 (P = 0.001)						
04 >=6 months treatment prior to randomisation / >=12 months of randomised treatment						
Frank1990 Y O C	12/53	35/49		2.82	-0.49 [-0.66, -0.32]	0
Georgotas1989 E O C	9/29	15/23		1.65	-0.34 [-0.60, -0.08]	0
KORNSTEIN2006A Y ?	20/73	43/66		3.12	-0.38 [-0.53, -0.22]	0
Keller1998 Y O C	5/77	19/84		4.24	-0.16 [-0.27, -0.06]	0
Kupfer1992 Y O C	1/11	6/9		1.01	-0.58 [-0.93, -0.22]	0
PREVENT study A Y O	30/129	54/129		4.06	-0.19 [-0.30, -0.07]	0
PREVENT study B Y O	3/43	18/40		2.78	-0.38 [-0.55, -0.21]	0
Wilson2003 E P C	25/56	31/57		2.58	-0.10 [-0.28, 0.09]	0
Subtotal (95% CI)	471	457		22.27	-0.30 [-0.41, -0.19]	
Total events: 105 (Treatment), 221 (Control)						
Test for heterogeneity: Chi ² = 22.64, df = 7 (P = 0.002), I ² = 69.1%						
Test for overall effect: Z = 5.57 (P < 0.00001)						
Total (95% CI)	2688	2294		100.00	-0.25 [-0.29, -0.22]	
Total events: 560 (Treatment), 1061 (Control)						
Test for heterogeneity: Chi ² = 72.00, df = 31 (P < 0.0001), I ² = 56.9%						


Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 04 SSRIs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 05 SSRIs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 06 SSRIs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 07 TCAs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 08 TCAs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 09 TCAs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 10 Venlafaxine or duloxetine: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 11 Venlafaxine or duloxetine: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)
 Outcome: 12 Venlafaxine or duloxetine: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 02 Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 03 Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 04 SSRIs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 05 SSRIs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 06 SSRIs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 07 TCAs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 08 TCAs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 09 TCAs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 10 Venlafaxine or duloxetine: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 11 Venlafaxine or duloxetine: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)
 Outcome: 12 Venlafaxine or duloxetine: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)
 Outcome: 02 Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)
 Outcome: 03 Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)
 Outcome: 04 SSRIs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)
 Outcome: 05 SSRIs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)
 Outcome: 06 SSRIs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)
 Outcome: 07 TCAs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)
 Outcome: 08 TCAs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)
 Outcome: 09 TCAs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment): at least 1 previous episode




Review: Pharmacology: Relapse prevention
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)
 Outcome: 02 Number of patients with relapse of depression (by randomised study time): at least one previous episode




Review: Pharmacology: Relapse prevention
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)
 Outcome: 03 Number of patients with relapse of depression (2x2 analysis): at least one previous episode




Review: Pharmacology: Relapse prevention
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)
 Outcome: 04 Number of patients with relapse of depression (by pre-randomisation treatment): first episode




Review: Pharmacology: Relapse prevention
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)
 Outcome: 05 Number of patients with relapse of depression (by randomised study time): first episode




Review: Pharmacology: Relapse prevention
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)
 Outcome: 06 Number of patients with relapse of depression (2x2 analysis): first episode




Review: Pharmacology: Relapse prevention
 Comparison: 05 Responders randomised to lithium maintenance treatment or placebo (2x2 time analyses)
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 06 Responders randomised to maintenance treatment or placebo
 Outcome: 01 Number of patients with relapse of depression (by length of time in remission)




Review: Pharmacology: Relapse prevention
 Comparison: 06 Responders randomised to maintenance treatment or placebo
 Outcome: 02 Number of patients with relapse of depression (by length of time in remission/length of randomised treatment)




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 01 Relapses during 1st month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 02 Relapses during 2nd month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 03 Relapses during 3rd month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 04 Relapses during 4th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 05 Relapses during 5th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 06 Relapses during 6th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 07 Relapses during 7th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 08 Relapses during 8th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 09 Relapses during 9th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 10 Relapses during 10th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 11 Relapses during 11th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 12 Relapses during 12th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 13 Relapses during 13th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 14 Relapses during 14th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 15 Relapses during 15th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 16 Relapses during 16th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 17 Relapses during 17th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 18 Relapses during 18th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 19 Relapses during 19th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 20 Relapses during and after 20th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 01 Relapses during 1st month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 02 Relapses during 2nd month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 03 Relapses during 3rd month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 04 Relapses during 4th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 05 Relapses during 5th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 06 Relapses during 6th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 07 Relapses during 7th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 08 Relapses during 8th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 09 Relapses during 9th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 10 Relapses during 10th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 11 Relapses during 11th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 12 Relapses during 12th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 13 Relapses during 13th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 14 Relapses during 14th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 15 Relapses during 15th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 16 Relapses during 16th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 17 Relapses during 17th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 18 Relapses during 18th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 19 Relapses during 19th month of randomised treatment




Review: Pharmacology: Relapse prevention
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis
 Outcome: 20 Relapses during and after 20th month of randomised treatment



Review: Pharmacology: Relapse prevention
 Comparison: 09 Responders randomised to continue augmentation treatment or placebo (maintained on antidepressant)
 Outcome: 01 Number of patients with relapse (risperidone + citalopram vs placebo + citalopram)




Review: Pharmacology: Relapse prevention
 Comparison: 10 Responders to ECT randomised to continuation treatments
 Outcome: 01 Number of patients with relapse




SSRIs versus antidepressants


Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 01 Overall Efficacy




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 02 Efficacy in In-patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 03 Efficacy in Out-patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 04 Efficacy in Primary Care




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 05 Leaving the study early




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 06 Inpatients leaving the study early




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 07 Outpatients leaving the study early




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 08 Primary care patients leaving the study early




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 09 Leaving the study due to side effects




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 10 Inpatients leaving the study due to side effects




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 11 Outpatients leaving the study due to side effects




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 12 Primary care patients leaving the study due to side effects




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 13 Patients reporting adverse events




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 14 Inpatients reporting adverse events




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 01 SSRIs versus alternative antidepressants
 Outcome: 15 Outpatients reporting adverse events




Review: Pharmacology: SSRI's versus antidepressants
 Comparison: 01 SSRI's versus alternative antidepressants
 Outcome: 16 Primary care patients reporting adverse events




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 01 Overall Efficacy




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 02 Efficacy in In-patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 03 Efficacy in Out-patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 04 Efficacy in Primary Care




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 05 Leaving the study early (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 06 Inpatients leaving the study early (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 07 Outpatients leaving the study early (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 08 Primary care patients leaving the study early (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 09 Leaving the study due to side effects (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 10 Inpatients leaving the study due to side effects (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 11 Outpatients leaving the study due to side effects (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 12 Primary care patients leaving the study due to side effects (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 13 Patients reporting adverse events (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 14 Inpatients reporting adverse events (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 15 Outpatients reporting adverse events (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 02 SSRIs versus tricyclic antidepressants
 Outcome: 16 Primary care patients reporting adverse events (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 03 SSRIs versus 3rd generation ADs
 Outcome: 01 Overall Efficacy




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 03 SSRIs versus 3rd generation ADs
 Outcome: 02 Efficacy in In-patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 03 SSRIs versus 3rd generation ADs
 Outcome: 03 Efficacy in Out-patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 03 SSRIs versus 3rd generation ADs
 Outcome: 04 Efficacy in Primary Care patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 03 SSRIs versus 3rd generation ADs
 Outcome: 05 Leaving the study early




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 03 SSRIs versus 3rd generation ADs
 Outcome: 06 Leaving the study due to side effects




Review: Pharmacology: SSRI's versus antidepressants
 Comparison: 03 SSRI's versus 3rd generation ADs
 Outcome: 07 Patients reporting adverse events




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 04 SSRIs versus (venlafaxine or mirtazapine)
 Outcome: 01 Overall Efficacy




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 04 SSRIs versus (venlafaxine or mirtazapine)
 Outcome: 02 Efficacy in In-patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 04 SSRIs versus (venlafaxine or mirtazapine)
 Outcome: 03 Efficacy in Out-patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 04 SSRIs versus (venlafaxine or mirtazapine)
 Outcome: 04 Efficacy in Primary Care patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 05 SSRIs versus MAOIs
 Outcome: 01 Overall Efficacy



Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 05 SSRIs versus MAOIs
 Outcome: 02 Efficacy in In-patients




Review: Pharmacology: SSRIs versus antidepressants
 Comparison: 05 SSRIs versus MAOIs
 Outcome: 03 Efficacy in Out-patients




SSRIs versus placebo


Review: Pharmacology: SSRIs versus placebo
 Comparison: 01 Overall efficacy
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: SSRIs versus placebo
 Comparison: 01 Overall efficacy
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: SSRIs versus placebo
 Comparison: 01 Overall efficacy
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: SSRIs versus placebo
 Comparison: 02 Overall Tolerability
 Outcome: 01 Leaving the study early




Review: Pharmacology: SSRIs versus placebo
 Comparison: 02 Overall Tolerability
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: SSRI's versus placebo
 Comparison: 02 Overall Tolerability
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: SSRIs versus placebo
 Comparison: 02 Overall Tolerability
 Outcome: 04 Sensitivity analysis: Leaving the study early




Review: Pharmacology: SSRIs versus placebo
 Comparison: 03 Overall efficacy by severity
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: SSRIs versus placebo
 Comparison: 03 Overall efficacy by severity
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: SSRIs versus placebo
 Comparison: 03 Overall efficacy by severity
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: SSRIs versus placebo
 Comparison: 04 Overall Tolerability: trials >=8 weeks long
 Outcome: 01 Leaving the study early




Review: Pharmacology: SSRIs versus placebo
 Comparison: 04 Overall Tolerability: trials >=8 weeks long
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: SSRIs versus placebo
 Comparison: 04 Overall Tolerability: trials >=8 weeks long
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: SSRIs versus placebo
 Comparison: 05 Overall efficacy: trials >=8 weeks long
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: SSRIs versus placebo
 Comparison: 05 Overall efficacy: trials >=8 weeks long
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: SSRIs versus placebo
 Comparison: 05 Overall efficacy: trials >=8 weeks long
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: SSRIs versus placebo
 Comparison: 06 Overall efficacy by severity: trials >=8 weeks long
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score



Review: Pharmacology: SSRIs versus placebo
 Comparison: 06 Overall efficacy by severity: trials >=8 weeks long
 Outcome: 02 Number of people not achieving remission



Review: Pharmacology: SSRIs versus placebo
 Comparison: 06 Overall efficacy by severity: trials >=8 weeks long
 Outcome: 03 Mean endpoint scores




TCAs versus placebo

TCA.01. TCAs versus placebo – efficacy data


TCA.01.01. Mean endpoint depression scores

Review: Depression update: pharmacology TCAs vs placebo
 Comparison: 01 Efficacy data
 Outcome: 01 Mean endpoint depression scores




TCA.01.02. Mean depression change scores

Review: Depression update: pharmacology TCAs vs placebo
 Comparison: 01 Efficacy data
 Outcome: 02 Mean depression change scores




TCA.01.03. Mean depression change scores (sensitivity analysis)

Review: Depression update: pharmacology TCAs vs placebo
 Comparison: 01 Efficacy data
 Outcome: 03 Sensitivity analysis: Mean depression change scores




TCA.01.04. Non-remission data

Review: Depression update: pharmacology TCAs vs placebo
 Comparison: 01 Efficacy data
 Outcome: 04 Number not achieving remission




TCA.01.05. Non-response data

Review: Depression update: pharmacology TCAs vs placebo
 Comparison: 01 Efficacy data
 Outcome: 05 Number not achieving response (50% reduction in depression scores)



TCA.01.06. Non-response data (sensitivity analysis)


Review: Depression update: pharmacology TCAs vs placebo
 Comparison: 01 Efficacy data
 Outcome: 06 Sensitivity analysis: Number not achieving response (50% reduction in depression scores)



TCA.02. TCAs versus placebo - acceptability and tolerability data


TCA.02.01. Number leaving treatment early for any reason

Review: Depression update: pharmacology TCAs vs placebo
 Comparison: 02 Acceptability and tolerability data
 Outcome: 01 Number leaving treatment early for any reason




TCA.02.02. Number leaving treatment early due to side effects

Review: Depression update: pharmacology TCAs vs placebo
 Comparison: 02 Acceptability and tolerability data
 Outcome: 02 Number leaving treatment early due to side effects




TCA.02.03. Number reporting side effects

Review: Depression update: pharmacology TCAs vs placebo
 Comparison: 02 Acceptability and tolerability data
 Outcome: 03 Number reporting side effects




Venlafaxine


Review: Pharmacology: Venlafaxine
 Comparison: 01 Venlafaxine versus other antidepressants
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 01 Venlafaxine versus other antidepressants
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 01 Venlafaxine versus other antidepressants
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 01 Venlafaxine versus other antidepressants
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 01 Venlafaxine versus other antidepressants
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 01 Venlafaxine versus other antidepressants
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 03 Venlafaxine versus SSRIs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 03 Venlafaxine versus SSRIs
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 03 Venlafaxine versus SSRIs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 03 Venlafaxine versus SSRIs
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 03 Venlafaxine versus SSRIs
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 03 Venlafaxine versus SSRIs
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 04 Venlafaxine versus TCAs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 04 Venlafaxine versus TCAs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 04 Venlafaxine versus TCAs
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 04 Venlafaxine versus TCAs
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 04 Venlafaxine versus TCAs
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 11 Venlafaxine versus SSRIs in inpatients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 11 Venlafaxine versus SSRIs in inpatients
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 11 Venlafaxine versus SSRIs in inpatients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 11 Venlafaxine versus SSRIs in inpatients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 11 Venlafaxine versus SSRIs in inpatients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 11 Venlafaxine versus SSRIs in inpatients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 12 Venlafaxine versus SSRIs in outpatients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 12 Venlafaxine versus SSRIs in outpatients
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 12 Venlafaxine versus SSRIs in outpatients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 12 Venlafaxine versus SSRIs in outpatients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 12 Venlafaxine versus SSRIs in outpatients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 12 Venlafaxine versus SSRIs in outpatients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 14 Venlafaxine versus TCAs in inpatients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 14 Venlafaxine versus TCAs in inpatients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 14 Venlafaxine versus TCAs in inpatients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 14 Venlafaxine versus TCAs in inpatients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 14 Venlafaxine versus TCAs in inpatients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 15 Venlafaxine versus TCAs in outpatients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 15 Venlafaxine versus TCAs in outpatients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 15 Venlafaxine versus TCAs in outpatients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 15 Venlafaxine versus TCAs in outpatients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 15 Venlafaxine versus TCAs in outpatients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 16 Venlafaxine versus TCAs in primary care patients
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 16 Venlafaxine versus TCAs in primary care patients
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 16 Venlafaxine versus TCAs in primary care patients
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 16 Venlafaxine versus TCAs in primary care patients
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 16 Venlafaxine versus TCAs in primary care patients
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 18 Venlafaxine (<= 150 mg) versus other antidepressants
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 18 Venlafaxine (<= 150 mg) versus other antidepressants
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 18 Venlafaxine (<= 150 mg) versus other antidepressants
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 18 Venlafaxine (<=150 mg) versus other antidepressants
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 18 Venlafaxine (<=150 mg) versus other antidepressants
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 18 Venlafaxine (<=150 mg) versus other antidepressants
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 19 Venlafaxine (<= 150 mg) versus SSRIs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 20 Venlafaxine (<= 150 mg) versus TCAs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 20 Venlafaxine (<=150 mg) versus TCAs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 20 Venlafaxine (<=150 mg) versus TCAs
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 20 Venlafaxine (<=150 mg) versus TCAs
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 20 Venlafaxine (<= 150 mg) versus TCAs
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 21 Venlafaxine (>=150 mg) versus other antidepressants
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 21 Venlafaxine (>=150 mg) versus other antidepressants
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 21 Venlafaxine (>= 150 mg) versus other antidepressants
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 21 Venlafaxine (>=150 mg) versus other antidepressants
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 21 Venlafaxine (>=150 mg) versus other antidepressants
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 21 Venlafaxine (>= 150 mg) versus other antidepressants
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 22 Venlafaxine (>= 150 mg) versus TCAs and SSRIs (not mirtazapine)
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 22 Venlafaxine (>=150 mg) versus TCAs and SSRIs (not mirtazapine)
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 22 Venlafaxine (>= 150 mg) versus TCAs and SSRIs (not mirtazapine)
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 22 Venlafaxine (>=150 mg) versus TCAs and SSRIs (not mirtazapine)
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 22 Venlafaxine (>=150 mg) versus TCAs and SSRIs (not mirtazapine)
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 22 Venlafaxine (>=150 mg) versus TCAs and SSRIs (not mirtazapine)
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 23 Venlafaxine (>= 150 mg) versus SSRIs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 23 Venlafaxine (>=150 mg) versus SSRIs
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 23 Venlafaxine (>= 150 mg) versus SSRIs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 23 Venlafaxine (>=150 mg) versus SSRIs
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 23 Venlafaxine (>=150 mg) versus SSRIs
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 23 Venlafaxine (>=150 mg) versus SSRIs
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 24 Venlafaxine (>=150 mg) versus TCAs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 24 Venlafaxine (>150mg) versus other antidepressants
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 24 Venlafaxine (>=150 mg) versus TCAs
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 24 Venlafaxine (>=150 mg) versus TCAs
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 24 Venlafaxine (>= 150 mg) versus TCAs
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 24 Venlafaxine (>= 150 mg) versus TCAs
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 25 Venlafaxine (>150 mg) versus other antidepressants
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 25 Venlafaxine (>150 mg) versus other antidepressants
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 25 Venlafaxine (>150 mg) versus other antidepressants
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine
 Comparison: 25 Venlafaxine (>150 mg) versus other antidepressants
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine
 Comparison: 25 Venlafaxine (> 150 mg) versus other antidepressants
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine
 Comparison: 25 Venlafaxine (>150 mg) versus other antidepressants
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine
 Comparison: 26 Venlafaxine (>150 mg) versus SSRIs
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine
 Comparison: 26 Venlafaxine (>150 mg) versus SSRIs
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine
 Comparison: 26 Venlafaxine (> 150 mg) versus SSRIs
 Outcome: 03 Mean endpoint scores



Review: Pharmacology: Venlafaxine
 Comparison: 26 Venlafaxine (> 150 mg) versus SSRIs
 Outcome: 04 Leaving the study early



Review: Pharmacology: Venlafaxine
 Comparison: 26 Venlafaxine (>150 mg) versus SSRIs
 Outcome: 05 Leaving the study early due to side effects



Review: Pharmacology: Venlafaxine
 Comparison: 26 Venlafaxine (>150 mg) versus SSRIs
 Outcome: 06 Patients reporting side effects

